We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.


Any AUS or NZ company


Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of IMC: rating 5
(5 out of 5)



Automic Group Level 5, 126 Phillip Street Sydney NSW 2000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000IMC7
Address: Level 3 62 Lygon Street Carlton Vic 3053 Australia
Tel:  +61 (0) 3 9824 5254 Fax: +61 (0)3 9822 7735

Date first listed: 30/04/1999
Company Secretary: Phillip Hains
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ

News & Events

Expand this box to read and print

The suspension of trading in the securities of Immuron Limited will be lifted from the commencement of trading on 24 September 2021, following the release by IMC of an announcement regarding a planned acquisition


The Company has been pursuing a major acquisition of a private biotechnology company focused on the development of innovative vaccine technologies. After filing with the ASX a detailed ASX In-Principal Advice Application and subsequent lengthy discussions and exchanges with the ASX. ASX advised Immuron that based on the information provided to date, ASX does not currently have sufficient information to enable it to be satisfied that the combined group after the proposed acquisition would meet those requirements under chapters 1 and 2 of the ASX Listing Rules. Immuron as a result is now unable to satisfy the pre-conditions for this proposed acquisition due to the expiration of the existing contractual timetable and will not proceed with the proposed acquisition in its present form. There are no break fees associated with being unable to satisfy the preconditions existing contractual timetable, however professional fees associated with thistransaction over the past 4 months are approximately $450k plus GST.


The company lodges its Preliminary Final Report.


Immuron is required to lodge a formal In-Principle Advice Application in accordance with Guidance Note 12. That application has now been received by ASX, and the ASX is currently considering the application in connection with Immuron's suitability for admission to the official list of ASX Limited. Immuron acknowledges that its securities will remain suspended until it has met the requirements set out in Guidance Note 12.


The company is limited in the detail that can be released at this time while the ASX consider a submission it has requested from the Company in relation to ASX Listing Rule 11.1 and 11.2 and Guidance Note 12.


The securities of Immuron Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMC, pending the release of an announcement regarding a planned acquisition.


we understand that on or about this date the company consolidated its shares 1 for 40


The suspension of trading in the securities of Immuron Limited (the "Company") will be lifted immediately, following the release of an announcement of a capital raising. Security Code: IMC


The securities of Immuron Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a capital raising


name changed from Anadis Limited



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    20/11/2020Daniel Pollock-100,000$0.260$26,000
    23/06/2020Daniel Pollock-100,000$0.325$32,500
    17/06/2020Peter Anastasiou-4,184,808$0.312$1,306,326
    11/06/2020Daniel Pollock-100,000$0.405$40,480
    19/07/2019Gary Jacob260,000$0.081

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Roger AstonNon Exec Chairman25/05/2012
    Jerry KanellosCEO28/07/2015
    Daniel PollockNon Exec Director11/10/2012
    Steve AnastasiouNon Exec Director28/05/2013
    Ravi SavarirayanDirector07/04/2017

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Peter AnastasiouVice Chairman21/05/201524/09/2021
    Gary JacobManaging Director, CEO19/11/201825/03/2020
    Richard BermanDirector01/07/201817/10/2019
    Thomas LiquardCEO31/08/201503/08/2017
    Leearne HinchCEO02/04/201508/07/2015
    Amos MeltzerCEO28/02/201302/04/2015
    Elane ZelcerDeputy Chairman19/11/200902/09/2013
    Stewart WasherNon Exec Director08/02/201203/07/2013
    Graeme StevensCFO22/11/200719/04/2013
    Joe BainiManaging Director, CEO17/01/201128/02/2013
    Colin ChapmanExecutive Chairman17/12/200808/10/2012
    Roy Robins-BrowneNon Exec Director02/02/199807/02/2012
    Simon SalkaNon Exec Director18/06/200807/02/2012
    Arie NudelDirector12/07/200526/03/2010
    Zeil RosenbergExecutive Director, CEO18/06/200819/07/2009
    Peter JenkinsNon Exec Director17/01/199411/02/2009
    Roman ZwolenskiChairman24/09/200220/06/2008
    Philip MolyneuxNon Exec Chairman15/01/199822/07/2007
    Conor GrahamManaging Director, CEO01/05/199714/04/2007

    Date of first appointment, title may have changed.